Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyIdentification
- Name
- Torasemide
- Accession Number
- DB00214 (APRD00295, APRD00217)
- Type
- Small Molecule
- Groups
- Approved
- Description
Torasemide (rINN) or torsemide (USAN) is a pyridine-sulfonylurea type loop diuretic mainly used in the management of edema associated with congestive heart failure. It is also used at low doses for the management of hypertension. It is marketed under the brand name Demadex. [Wikipedia]
- Structure
Structure for DB00214 (Torasemide)
- Synonyms
- 1-Isopropyl-3-((4-m-toluidino-3-pyridyl)sulfonyl)urea
- Luprac
- N-(((1-Methylethyl)amino)carbonyl)-4-((3-methylphenyl)amino)-3-pyridinesulfonamide
- Torasemida
- Torasemidum
- Torsemide
- External IDs
- AC-4464 / AC4464 / BM02.015
- Product Images
- Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Demadex Tablet 100 mg/1 Oral Meda Pharmaceuticals Ltd 2015-01-01 Not applicable US 
Demadex Tablet 100 mg/1 Oral Meda Pharmaceuticals Ltd 2009-02-20 2016-01-20 US Demadex Tablet 20 mg/1 Oral Physicians Total Care, Inc. 2009-10-21 Not applicable US Demadex Tablet 10 mg/1 Oral Meda Pharmaceuticals Ltd 2009-02-20 2016-01-20 US Demadex Tablet 10 mg/1 Oral Physicians Total Care, Inc. 2000-11-28 Not applicable US Demadex Tablet 10 mg/1 Oral Meda Pharmaceuticals Ltd 2015-01-01 2019-06-30 US Demadex Tablet 20 mg/1 Oral Meda Pharmaceuticals Ltd 2015-01-01 2018-11-30 US Demadex Tablet 5 mg/1 Oral Meda Pharmaceuticals Ltd 2009-02-20 2016-01-20 US Demadex Tablet 5 mg/1 Oral Meda Pharmaceuticals Ltd 2015-01-01 2018-04-05 US Demadex Tablet 20 mg/1 Oral Meda Pharmaceuticals Ltd 2009-02-20 2016-01-20 US - Generic Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Torsemide Tablet 20 mg/1 Oral Citron Pharma LLC 2007-10-17 Not applicable US Torsemide Tablet 20 mg/1 Oral Avera Mc Kennan Hospital 2016-01-26 Not applicable US Torsemide Tablet 10 mg/1 Oral Av Pak 2014-10-07 Not applicable US Torsemide Tablet 20 mg/1 Oral Amerincan Health Packaging 2013-07-22 Not applicable US Torsemide Tablet 5 mg/1 Oral Qualitest 2011-03-22 2016-11-08 US Torsemide Injection, solution 10 mg/mL Intravenous American Regent 2010-05-26 Not applicable US Torsemide Tablet 10 mg/1 Oral Cardinal Health 2010-01-14 2018-03-09 US Torsemide Tablet 5 mg/1 Oral Teva 2004-06-01 Not applicable US 
Torsemide Tablet 5 mg/1 Oral Par Pharmaceutical 2009-01-27 2016-10-13 US Torsemide Tablet 100 mg/1 Oral Apotex Corporation 2005-06-06 Not applicable US - International/Other Brands
- Demadex / Diuver / Examide / Luprac
- Categories
- Amides
- Antihypertensive Agents
- Cardiovascular Agents
- Cardiovascular System
- Cytochrome P-450 CYP2C19 Inhibitors
- Cytochrome P-450 CYP2C8 Substrates
- Cytochrome P-450 CYP2C9 Substrates
- Cytochrome P-450 Enzyme Inhibitors
- Diuretics
- High-Ceiling Diuretics
- Hyperglycemia-Associated Agents
- Hypotensive Agents
- Membrane Transport Modulators
- Natriuretic Agents
- Sodium Potassium Chloride Symporter Inhibitors
- Sulfonamides, Plain
- Sulfones
- Sulfur Compounds
- UNII
- W31X2H97FB
- CAS number
- 56211-40-6
- Weight
- Average: 348.42
Monoisotopic: 348.125611216 - Chemical Formula
- C16H20N4O3S
- InChI Key
- NGBFQHCMQULJNZ-UHFFFAOYSA-N
- InChI
- InChI=1S/C16H20N4O3S/c1-11(2)18-16(21)20-24(22,23)15-10-17-8-7-14(15)19-13-6-4-5-12(3)9-13/h4-11H,1-3H3,(H,17,19)(H2,18,20,21)
- IUPAC Name
- 1-({4-[(3-methylphenyl)amino]pyridin-3-yl}sulfonyl)-3-(propan-2-yl)urea
- SMILES
- CC(C)NC(=O)NS(=O)(=O)C1=C(NC2=CC=CC(C)=C2)C=CN=C1
Pharmacology
- Indication
For the treatment of edema associated with congestive heart failure, renal disease, or hepatic disease. Also for the treatment of hypertension alone or in combination with other antihypertensive agents.
- Structured Indications
- Pharmacodynamics
Torasemide (INN) or torsemide (USAN) is a novel loop diuretic belonging to pridine sulphonyl urea. It differs form other thiazide diuretics in that a double ring system is incorporated into its structure. Like thiazides, loop diuretics must be secreted into the tubular fluid by proximal tubule cells. In the thick ascending loop Na+ and Cl- reabsorption is accomplished by a Na+/K+/2Cl- symporter. The thick ascending limb has a high reabsorptive capacity and is responsible for reabsorbing 25% of the filtered load of Na+. The loop diuretics act by blocking this symporter. Because of the large absorptive capacity and the amount of Na+ delivered to the ascending limb, loop diuretics have a profound diuretic action. In addition, more distal nephron segments do not have the reabsorptive capacity to compensate for this increased load. The osmotic gradient for water reabsorption is also reduced resulting in an increase in the amount of water excreted.
- Mechanism of action
Torasemide inhibits the Na+/K+/2Cl--carrier system (via interference of the chloride binding site) in the lumen of the thick ascending portion of the loop of Henle, resulting in a decrease in reabsorption of sodium and chloride. This results in an increase in the rate of delivery of tubular fluid and electrolytes to the distal sites of hydrogen and potassium ion secretion, while plasma volume contraction increases aldosterone production. The increased delivery and high aldosterone levels promote sodium reabsorption at the distal tubules, and By increasing the delivery of sodium to the distal renal tubule, torasemide indirectly increases potassium excretion via the sodium-potassium exchange mechanism. Torasemide's effects in other segments of the nephron have not been demonstrated. Thus torasemide increases the urinary excretion of sodium, chloride, and water, but it does not significantly alter glomerular filtration rate, renal plasma flow, or acid-base balance. Torasemide's effects as a antihypertensive are due to its diuretic actions. By reducing extracellular and plasma fluid volume, blood pressure is reduced temporarily, and cardiac output also decreases.
Target Actions Organism ASolute carrier family 12 member 1 inhibitorHuman - Absorption
Rapidly absorbed following oral administration. Absolute bioavailability is 80%. Food has no effect on absorption.
- Volume of distribution
- 12 to 15 L [normal adults or in patients with mild to moderate renal failure or congestive heart failure]
- Protein binding
> 99%
- Metabolism
Metabolized via the hepatic CYP2C8 to 5 metabolites. The major metabolite, M5, is pharmacologically inactive. There are 2 minor metabolites, M1, possessing one-tenth the activity of torasemide, and M3, equal in activity to torasemide. Overall, torasemide appears to account for 80% of the total diuretic activity, while metabolites M1 and M3 account for 9% and 11%, respectively.
- Route of elimination
Torsemide is cleared from the circulation by both hepatic metabolism (approximately 80% of total clearance) and excretion into the urine (approximately 20% of total clearance in patients with normal renal function).
- Half life
3.5 hours
- Clearance
- Not Available
- Toxicity
Symptoms of overdose include dehydration, hypovolemia, hypotension, hyponatremia, hypokalemia, hypochloremic alkalosis, and hemoconcentration. Oral LD50 in rat is 5 g/kg, and intravenous LD50 in rat is 500 mg/kg.
- Affected organisms
- Humans and other mammals
- Pathways
Pathway Category Torsemide Action Pathway Drug action - Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Drug group (4R)-limonene The therapeutic efficacy of Torasemide can be decreased when used in combination with (4R)-limonene. Investigational 16-Bromoepiandrosterone 16-Bromoepiandrosterone may increase the hypokalemic activities of Torasemide. Investigational 19-norandrostenedione 19-norandrostenedione may increase the hypokalemic activities of Torasemide. Experimental, Illicit 2,4-thiazolidinedione The therapeutic efficacy of 2,4-thiazolidinedione can be decreased when used in combination with Torasemide. Investigational 5-androstenedione 5-androstenedione may increase the hypokalemic activities of Torasemide. Experimental, Illicit 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Torasemide. Experimental Abiraterone The serum concentration of Torasemide can be increased when it is combined with Abiraterone. Approved Acarbose The therapeutic efficacy of Acarbose can be decreased when used in combination with Torasemide. Approved, Investigational Acebutolol Torasemide may increase the hypotensive activities of Acebutolol. Approved, Investigational Aceclofenac The therapeutic efficacy of Torasemide can be decreased when used in combination with Aceclofenac. Approved, Investigational Acemetacin The therapeutic efficacy of Torasemide can be decreased when used in combination with Acemetacin. Approved, Experimental, Investigational Acetohexamide The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Torasemide. Approved, Investigational, Withdrawn Acetyldigitoxin The risk or severity of adverse effects can be increased when Torasemide is combined with Acetyldigitoxin. Approved Acetyldigoxin The risk or severity of adverse effects can be increased when Torasemide is combined with Acetyldigoxin. Experimental Acetylsalicylic acid The therapeutic efficacy of Torasemide can be decreased when used in combination with Acetylsalicylic acid. Approved, Vet Approved Aclarubicin The serum concentration of Aclarubicin can be increased when it is combined with Torasemide. Investigational Adapalene The therapeutic efficacy of Torasemide can be decreased when used in combination with Adapalene. Approved AICA ribonucleotide The therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Torasemide. Experimental, Investigational Alclofenac The therapeutic efficacy of Torasemide can be decreased when used in combination with Alclofenac. Approved, Withdrawn Alclometasone Alclometasone may increase the hypokalemic activities of Torasemide. Approved Alcuronium Torasemide may decrease the neuromuscular blocking activities of Alcuronium. Experimental Aldesleukin The risk or severity of adverse effects can be increased when Aldesleukin is combined with Torasemide. Approved Aldosterone Aldosterone may increase the hypokalemic activities of Torasemide. Experimental, Investigational Aldoxorubicin The serum concentration of Aldoxorubicin can be increased when it is combined with Torasemide. Investigational Alfentanil The risk or severity of adverse effects can be increased when Alfentanil is combined with Torasemide. Approved, Illicit Alfuzosin Alfuzosin may increase the hypotensive activities of Torasemide. Approved, Investigational Aliskiren Torasemide may increase the hypotensive activities of Aliskiren. Approved, Investigational Allicin The therapeutic efficacy of Allicin can be decreased when used in combination with Torasemide. Investigational Allopurinol The risk or severity of adverse effects can be increased when Torasemide is combined with Allopurinol. Approved Alminoprofen The therapeutic efficacy of Torasemide can be decreased when used in combination with Alminoprofen. Experimental Alogliptin The therapeutic efficacy of Alogliptin can be decreased when used in combination with Torasemide. Approved Aloxiprin The therapeutic efficacy of Torasemide can be decreased when used in combination with Aloxiprin. Experimental Alphacetylmethadol The risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Torasemide. Experimental, Illicit Alphaprodine The risk or severity of adverse effects can be increased when Alphaprodine is combined with Torasemide. Illicit Alprenolol Torasemide may increase the hypotensive activities of Alprenolol. Approved, Withdrawn Ambrisentan Torasemide may increase the hypotensive activities of Ambrisentan. Approved, Investigational Amcinonide Amcinonide may increase the hypokalemic activities of Torasemide. Approved Amifostine Torasemide may increase the hypotensive activities of Amifostine. Approved, Investigational Amikacin The serum concentration of Amikacin can be increased when it is combined with Torasemide. Approved, Investigational, Vet Approved Amiloride The risk or severity of adverse effects can be increased when Torasemide is combined with Amiloride. Approved Aminosalicylic Acid The therapeutic efficacy of Torasemide can be decreased when used in combination with Aminosalicylic Acid. Approved Amiodarone The metabolism of Torasemide can be decreased when combined with Amiodarone. Approved, Investigational Amlodipine Torasemide may increase the hypotensive activities of Amlodipine. Approved Amobarbital Amobarbital may increase the hypotensive activities of Torasemide. Approved, Illicit Amphetamine Amphetamine may increase the hypotensive activities of Torasemide. Approved, Illicit, Investigational Amphotericin B The risk or severity of adverse effects can be increased when Amphotericin B is combined with Torasemide. Approved, Investigational Amrubicin The serum concentration of Amrubicin can be increased when it is combined with Torasemide. Approved, Investigational Amyl Nitrite The risk or severity of adverse effects can be increased when Torasemide is combined with Amyl Nitrite. Approved Andrographolide The therapeutic efficacy of Torasemide can be decreased when used in combination with Andrographolide. Investigational Androstenedione Androstenedione may increase the hypokalemic activities of Torasemide. Experimental, Illicit Anecortave Anecortave may increase the hypokalemic activities of Torasemide. Investigational anecortave acetate anecortave acetate may increase the hypokalemic activities of Torasemide. Investigational Anisodamine The therapeutic efficacy of Torasemide can be decreased when used in combination with Anisodamine. Investigational Annamycin The serum concentration of Annamycin can be increased when it is combined with Torasemide. Investigational Antipyrine The therapeutic efficacy of Torasemide can be decreased when used in combination with Antipyrine. Approved, Investigational Apalutamide The serum concentration of Torasemide can be decreased when it is combined with Apalutamide. Approved, Investigational Apocynin The therapeutic efficacy of Torasemide can be decreased when used in combination with Apocynin. Investigational Apomorphine The risk or severity of adverse effects can be increased when Apomorphine is combined with Torasemide. Approved, Investigational Apraclonidine The risk or severity of adverse effects can be increased when Torasemide is combined with Apraclonidine. Approved Apramycin The serum concentration of Apramycin can be increased when it is combined with Torasemide. Experimental, Vet Approved Apremilast The therapeutic efficacy of Torasemide can be decreased when used in combination with Apremilast. Approved, Investigational Aprepitant The metabolism of Torasemide can be increased when combined with Aprepitant. Approved, Investigational Arbekacin The serum concentration of Arbekacin can be increased when it is combined with Torasemide. Approved, Investigational Arbutamine Arbutamine may increase the hypokalemic activities of Torasemide. Approved Arformoterol Arformoterol may increase the hypokalemic activities of Torasemide. Approved, Investigational Aripiprazole Aripiprazole may increase the hypotensive activities of Torasemide. Approved, Investigational Arotinolol The risk or severity of adverse effects can be increased when Arotinolol is combined with Torasemide. Investigational Arsenic trioxide The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Torasemide. Approved, Investigational Atamestane Atamestane may increase the hypokalemic activities of Torasemide. Investigational Atenolol Torasemide may increase the hypotensive activities of Atenolol. Approved Atracurium Torasemide may decrease the neuromuscular blocking activities of Atracurium. Approved, Experimental, Investigational Atracurium besylate Torasemide may decrease the neuromuscular blocking activities of Atracurium besylate. Approved Avanafil Avanafil may increase the antihypertensive activities of Torasemide. Approved Azapropazone The therapeutic efficacy of Torasemide can be decreased when used in combination with Azapropazone. Withdrawn Azelastine The therapeutic efficacy of Torasemide can be decreased when used in combination with Azelastine. Approved Azilsartan medoxomil The risk or severity of adverse effects can be increased when Torasemide is combined with Azilsartan medoxomil. Approved, Investigational Balaglitazone The therapeutic efficacy of Balaglitazone can be decreased when used in combination with Torasemide. Investigational Balsalazide The therapeutic efficacy of Torasemide can be decreased when used in combination with Balsalazide. Approved, Investigational Bambuterol Bambuterol may increase the hypokalemic activities of Torasemide. Approved, Investigational Barbexaclone Barbexaclone may increase the hypotensive activities of Torasemide. Experimental Barbital Barbital may increase the hypotensive activities of Torasemide. Illicit Barnidipine Torasemide may increase the antihypertensive activities of Barnidipine. Approved Beclomethasone dipropionate Beclomethasone dipropionate may increase the hypokalemic activities of Torasemide. Approved, Investigational Bekanamycin The serum concentration of Bekanamycin can be increased when it is combined with Torasemide. Experimental Bempedoic acid The therapeutic efficacy of Bempedoic acid can be decreased when used in combination with Torasemide. Investigational Benazepril Torasemide may increase the hypotensive activities of Benazepril. Approved, Investigational Bendazac The therapeutic efficacy of Torasemide can be decreased when used in combination with Bendazac. Experimental Bendroflumethiazide Torasemide may increase the hypotensive activities of Bendroflumethiazide. Approved Benmoxin Benmoxin may increase the hypotensive activities of Torasemide. Withdrawn Benorilate The therapeutic efficacy of Torasemide can be decreased when used in combination with Benorilate. Experimental Benoxaprofen The therapeutic efficacy of Torasemide can be decreased when used in combination with Benoxaprofen. Withdrawn Benzydamine The therapeutic efficacy of Torasemide can be decreased when used in combination with Benzydamine. Approved Bepridil Torasemide may increase the hypotensive activities of Bepridil. Approved, Withdrawn Betamethasone Betamethasone may increase the hypokalemic activities of Torasemide. Approved, Vet Approved Betaxolol Betaxolol may increase the hypotensive activities of Torasemide. Approved, Investigational Bethanidine Bethanidine may increase the hypotensive activities of Torasemide. Approved Bevonium The therapeutic efficacy of Torasemide can be decreased when used in combination with Bevonium. Experimental Bezitramide The risk or severity of adverse effects can be increased when Bezitramide is combined with Torasemide. Experimental, Illicit, Withdrawn Bietaserpine Bietaserpine may increase the hypotensive activities of Torasemide. Experimental Bimatoprost Torasemide may increase the hypotensive activities of Bimatoprost. Approved, Investigational Bisoprolol Torasemide may increase the hypotensive activities of Bisoprolol. Approved Bortezomib The risk or severity of adverse effects can be increased when Bortezomib is combined with Torasemide. Approved, Investigational Bosentan Bosentan may increase the hypotensive activities of Torasemide. Approved, Investigational BQ-123 Torasemide may increase the hypotensive activities of BQ-123. Investigational Bretylium Torasemide may increase the hypotensive activities of Bretylium. Approved Brimonidine Brimonidine may increase the antihypertensive activities of Torasemide. Approved Brofaromine Brofaromine may increase the hypotensive activities of Torasemide. Experimental Bromfenac The therapeutic efficacy of Torasemide can be decreased when used in combination with Bromfenac. Approved Bromocriptine The risk or severity of adverse effects can be increased when Bromocriptine is combined with Torasemide. Approved, Investigational Bucillamine The therapeutic efficacy of Torasemide can be decreased when used in combination with Bucillamine. Investigational Budesonide Budesonide may increase the hypokalemic activities of Torasemide. Approved Bufexamac The therapeutic efficacy of Torasemide can be decreased when used in combination with Bufexamac. Approved, Experimental Buformin The therapeutic efficacy of Buformin can be decreased when used in combination with Torasemide. Investigational, Withdrawn Bumadizone The therapeutic efficacy of Torasemide can be decreased when used in combination with Bumadizone. Experimental Bumetanide The risk or severity of adverse effects can be increased when Torasemide is combined with Bumetanide. Approved Bupivacaine The risk or severity of adverse effects can be increased when Bupivacaine is combined with Torasemide. Approved, Investigational Bupranolol Torasemide may increase the hypotensive activities of Bupranolol. Approved Buprenorphine The risk or severity of adverse effects can be increased when Buprenorphine is combined with Torasemide. Approved, Illicit, Investigational, Vet Approved Butorphanol The risk or severity of adverse effects can be increased when Butorphanol is combined with Torasemide. Approved, Illicit, Vet Approved Cadralazine Cadralazine may increase the hypotensive activities of Torasemide. Experimental Cafedrine Torasemide may increase the hypotensive activities of Cafedrine. Investigational Canagliflozin The risk or severity of hypotension can be increased when Canagliflozin is combined with Torasemide. Approved Candesartan Torasemide may increase the hypotensive activities of Candesartan. Experimental Candesartan cilexetil The risk or severity of hypotension can be increased when Candesartan cilexetil is combined with Torasemide. Approved Candoxatril Torasemide may increase the hypotensive activities of Candoxatril. Experimental Capecitabine The metabolism of Torasemide can be decreased when combined with Capecitabine. Approved, Investigational Captopril Torasemide may increase the hypotensive activities of Captopril. Approved Carbamazepine The metabolism of Torasemide can be increased when combined with Carbamazepine. Approved, Investigational Carbaspirin calcium The therapeutic efficacy of Torasemide can be decreased when used in combination with Carbaspirin calcium. Experimental, Investigational Carbetocin The risk or severity of adverse effects can be increased when Carbetocin is combined with Torasemide. Approved, Investigational Carbutamide The therapeutic efficacy of Carbutamide can be decreased when used in combination with Torasemide. Experimental Carfentanil The risk or severity of adverse effects can be increased when Carfentanil is combined with Torasemide. Illicit, Investigational, Vet Approved Caroxazone Caroxazone may increase the hypotensive activities of Torasemide. Withdrawn Carprofen The therapeutic efficacy of Torasemide can be decreased when used in combination with Carprofen. Approved, Vet Approved, Withdrawn Carteolol Torasemide may increase the hypotensive activities of Carteolol. Approved Carvedilol Torasemide may increase the hypotensive activities of Carvedilol. Approved, Investigational Castanospermine The therapeutic efficacy of Torasemide can be decreased when used in combination with Castanospermine. Experimental Celecoxib The therapeutic efficacy of Torasemide can be decreased when used in combination with Celecoxib. Approved, Investigational Celiprolol Celiprolol may increase the hypokalemic activities of Torasemide. Approved, Investigational Ceritinib The serum concentration of Torasemide can be increased when it is combined with Ceritinib. Approved Chloroquine The therapeutic efficacy of Torasemide can be decreased when used in combination with Chloroquine. Approved, Investigational, Vet Approved Chlorothiazide Torasemide may increase the hypotensive activities of Chlorothiazide. Approved, Vet Approved Chlorpromazine The risk or severity of adverse effects can be increased when Chlorpromazine is combined with Torasemide. Approved, Investigational, Vet Approved Chlorpropamide The therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Torasemide. Approved, Investigational Chlorthalidone Torasemide may increase the hypotensive activities of Chlorthalidone. Approved Cholecalciferol The metabolism of Torasemide can be decreased when combined with Cholecalciferol. Approved, Nutraceutical Cholestyramine Cholestyramine can cause a decrease in the absorption of Torasemide resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Choline magnesium trisalicylate The therapeutic efficacy of Torasemide can be decreased when used in combination with Choline magnesium trisalicylate. Approved Ciclesonide Ciclesonide may increase the hypokalemic activities of Torasemide. Approved, Investigational Cicletanine Torasemide may increase the hypotensive activities of Cicletanine. Investigational Ciglitazone The therapeutic efficacy of Ciglitazone can be decreased when used in combination with Torasemide. Experimental Cilazapril Torasemide may increase the hypotensive activities of Cilazapril. Approved Cilnidipine The risk or severity of adverse effects can be increased when Cilnidipine is combined with Torasemide. Approved, Investigational Cilostazol The serum concentration of Cilostazol can be increased when it is combined with Torasemide. Approved, Investigational Cisatracurium Torasemide may decrease the neuromuscular blocking activities of Cisatracurium. Approved Cisplatin The risk or severity of ototoxicity and nephrotoxicity can be increased when Torasemide is combined with Cisplatin. Approved Clenbuterol Clenbuterol may increase the hypokalemic activities of Torasemide. Approved, Investigational, Vet Approved Clevidipine The risk or severity of adverse effects can be increased when Torasemide is combined with Clevidipine. Approved, Investigational Clobetasol Clobetasol may increase the hypokalemic activities of Torasemide. Approved, Investigational Clobetasol propionate Clobetasol propionate may increase the hypokalemic activities of Torasemide. Approved Clobetasone Clobetasone may increase the hypokalemic activities of Torasemide. Approved Clocortolone Clocortolone may increase the hypokalemic activities of Torasemide. Approved Clofarabine The risk or severity of adverse effects can be increased when Clofarabine is combined with Torasemide. Approved, Investigational Clomipramine The risk or severity of adverse effects can be increased when Clomipramine is combined with Torasemide. Approved, Investigational, Vet Approved Clonidine Clonidine may increase the hypotensive activities of Torasemide. Approved Clonixin The therapeutic efficacy of Torasemide can be decreased when used in combination with Clonixin. Approved Cloranolol Torasemide may increase the hypotensive activities of Cloranolol. Experimental Clotrimazole The metabolism of Torasemide can be decreased when combined with Clotrimazole. Approved, Vet Approved Clozapine The risk or severity of adverse effects can be increased when Clozapine is combined with Torasemide. Approved Codeine The risk or severity of adverse effects can be increased when Codeine is combined with Torasemide. Approved, Illicit Colesevelam Colesevelam can cause a decrease in the absorption of Torasemide resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Colestipol Colestipol can cause a decrease in the absorption of Torasemide resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Conivaptan The risk or severity of adverse effects can be increased when Conivaptan is combined with Torasemide. Approved, Investigational Cortexolone 17α-propionate Cortexolone 17α-propionate may increase the hypokalemic activities of Torasemide. Investigational Corticosterone Corticosterone may increase the hypokalemic activities of Torasemide. Experimental Cortisone acetate Cortisone acetate may increase the hypokalemic activities of Torasemide. Approved, Investigational Crisaborole The metabolism of Torasemide can be decreased when combined with Crisaborole. Approved, Investigational Cryptenamine Torasemide may increase the hypotensive activities of Cryptenamine. Approved Curcumin The therapeutic efficacy of Torasemide can be decreased when used in combination with Curcumin. Approved, Investigational Cyclopenthiazide Torasemide may increase the hypotensive activities of Cyclopenthiazide. Experimental Cyclosporine The risk or severity of adverse effects can be increased when Cyclosporine is combined with Torasemide. Approved, Investigational, Vet Approved Cyclothiazide Torasemide may increase the hypotensive activities of Cyclothiazide. Approved Cymarin The risk or severity of adverse effects can be increased when Torasemide is combined with Cymarin. Experimental Dabrafenib The serum concentration of Torasemide can be decreased when it is combined with Dabrafenib. Approved, Investigational Dapagliflozin The risk or severity of adverse effects can be increased when Torasemide is combined with Dapagliflozin. Approved Daunorubicin The serum concentration of Daunorubicin can be increased when it is combined with Torasemide. Approved Debrisoquin Debrisoquin may increase the hypotensive activities of Torasemide. Approved, Investigational Decamethonium Torasemide may decrease the neuromuscular blocking activities of Decamethonium. Approved Deferasirox The serum concentration of Torasemide can be increased when it is combined with Deferasirox. Approved, Investigational Deflazacort Deflazacort may increase the hypokalemic activities of Torasemide. Approved, Investigational Delapril Torasemide may increase the hypotensive activities of Delapril. Experimental Delavirdine The metabolism of Torasemide can be decreased when combined with Delavirdine. Approved Deoxyspergualin The therapeutic efficacy of Deoxyspergualin can be decreased when used in combination with Torasemide. Investigational Dersalazine The therapeutic efficacy of Torasemide can be decreased when used in combination with Dersalazine. Investigational Deserpidine Torasemide may increase the hypotensive activities of Deserpidine. Approved Desflurane The risk or severity of adverse effects can be increased when Desflurane is combined with Torasemide. Approved Deslanoside The risk or severity of adverse effects can be increased when Torasemide is combined with Deslanoside. Approved Desonide Desonide may increase the hypokalemic activities of Torasemide. Approved, Investigational Desoximetasone Desoximetasone may increase the hypokalemic activities of Torasemide. Approved Desoxycorticosterone acetate Desoxycorticosterone acetate may increase the hypokalemic activities of Torasemide. Approved Desoxycorticosterone Pivalate Desoxycorticosterone Pivalate may increase the hypokalemic activities of Torasemide. Experimental, Vet Approved Dexamethasone Dexamethasone may increase the hypokalemic activities of Torasemide. Approved, Investigational, Vet Approved Dexamethasone isonicotinate Dexamethasone isonicotinate may increase the hypokalemic activities of Torasemide. Vet Approved Dexmedetomidine The risk or severity of adverse effects can be increased when Torasemide is combined with Dexmedetomidine. Approved, Vet Approved Dextromoramide The risk or severity of adverse effects can be increased when Dextromoramide is combined with Torasemide. Experimental, Illicit Dextropropoxyphene The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Torasemide. Approved, Illicit, Investigational, Withdrawn Dezocine The risk or severity of adverse effects can be increased when Dezocine is combined with Torasemide. Approved, Investigational Diazoxide Diazoxide may increase the hypotensive activities of Torasemide. Approved Dibekacin The serum concentration of Dibekacin can be increased when it is combined with Torasemide. Experimental Diclofenac The therapeutic efficacy of Torasemide can be decreased when used in combination with Diclofenac. Approved, Vet Approved Diclofenamide The risk or severity of adverse effects can be increased when Torasemide is combined with Diclofenamide. Approved, Investigational Diethylnorspermine Torasemide may increase the hypotensive activities of Diethylnorspermine. Investigational Difenpiramide The therapeutic efficacy of Torasemide can be decreased when used in combination with Difenpiramide. Experimental Diflorasone Diflorasone may increase the hypokalemic activities of Torasemide. Approved Diflunisal The therapeutic efficacy of Torasemide can be decreased when used in combination with Diflunisal. Approved, Investigational Difluocortolone Difluocortolone may increase the hypokalemic activities of Torasemide. Approved, Investigational, Withdrawn Difluprednate Difluprednate may increase the hypokalemic activities of Torasemide. Approved Digitoxin The risk or severity of adverse effects can be increased when Torasemide is combined with Digitoxin. Approved, Investigational Digoxin The risk or severity of adverse effects can be increased when Torasemide is combined with Digoxin. Approved Digoxin Immune Fab (Ovine) The risk or severity of adverse effects can be increased when Torasemide is combined with Digoxin Immune Fab (Ovine). Approved Dihydralazine Dihydralazine may increase the hypotensive activities of Torasemide. Approved, Investigational Dihydrocodeine The risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Torasemide. Approved, Illicit Dihydroetorphine The risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Torasemide. Experimental, Illicit Dihydromorphine The risk or severity of adverse effects can be increased when Dihydromorphine is combined with Torasemide. Experimental, Illicit Dihydrostreptomycin The serum concentration of Dihydrostreptomycin can be increased when it is combined with Torasemide. Investigational, Vet Approved Diltiazem Torasemide may increase the hypotensive activities of Diltiazem. Approved, Investigational Dinutuximab The risk or severity of adverse effects can be increased when Torasemide is combined with Dinutuximab. Approved, Investigational Diphenoxylate The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Torasemide. Approved, Illicit Dipivefrin Dipivefrin may increase the hypokalemic activities of Torasemide. Approved Dipyridamole The risk or severity of adverse effects can be increased when Torasemide is combined with Dipyridamole. Approved Dobutamine Dobutamine may increase the hypokalemic activities of Torasemide. Approved Dofetilide The risk or severity of QTc prolongation, torsade de pointes, hypokalemia, hypomagnesemia, and cardiac arrest can be increased when Torasemide is combined with Dofetilide. Approved, Investigational Domoic Acid Torasemide may decrease the neuromuscular blocking activities of Domoic Acid. Experimental Dorzolamide Torasemide may increase the hypotensive activities of Dorzolamide. Approved Dosulepin The metabolism of Torasemide can be decreased when combined with Dosulepin. Approved Doxacurium chloride Torasemide may decrease the neuromuscular blocking activities of Doxacurium chloride. Approved Doxazosin Doxazosin may increase the hypotensive activities of Torasemide. Approved Doxofylline Doxofylline may increase the hypokalemic activities of Torasemide. Approved, Investigational Doxorubicin The serum concentration of Doxorubicin can be increased when it is combined with Torasemide. Approved, Investigational DPDPE The risk or severity of adverse effects can be increased when DPDPE is combined with Torasemide. Experimental Droxicam The therapeutic efficacy of Torasemide can be decreased when used in combination with Droxicam. Withdrawn Droxidopa Droxidopa may increase the hypokalemic activities of Torasemide. Approved, Investigational Dulaglutide The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Torasemide. Approved, Investigational Duloxetine Torasemide may increase the orthostatic hypotensive activities of Duloxetine. Approved Duvelisib The therapeutic efficacy of Torasemide can be decreased when used in combination with Duvelisib. Investigational E-6201 The therapeutic efficacy of Torasemide can be decreased when used in combination with E-6201. Investigational Efavirenz The metabolism of Torasemide can be decreased when combined with Efavirenz. Approved, Investigational Efonidipine Torasemide may increase the hypotensive activities of Efonidipine. Approved, Investigational Empagliflozin The risk or severity of adverse effects can be increased when Torasemide is combined with Empagliflozin. Approved Enalapril Torasemide may increase the hypotensive activities of Enalapril. Approved, Vet Approved Enalaprilat Torasemide may increase the hypotensive activities of Enalaprilat. Approved Endralazine Endralazine may increase the hypotensive activities of Torasemide. Experimental Epanolol Torasemide may increase the hypotensive activities of Epanolol. Experimental Ephedra Ephedra may increase the hypokalemic activities of Torasemide. Approved, Nutraceutical, Withdrawn Epinephrine Epinephrine may increase the hypokalemic activities of Torasemide. Approved, Vet Approved Epirizole The therapeutic efficacy of Torasemide can be decreased when used in combination with Epirizole. Approved Epirubicin The serum concentration of Epirubicin can be increased when it is combined with Torasemide. Approved Eplerenone The risk or severity of adverse effects can be increased when Torasemide is combined with Eplerenone. Approved Epoprostenol Torasemide may increase the hypotensive activities of Epoprostenol. Approved Eprosartan Torasemide may increase the hypotensive activities of Eprosartan. Approved Equilenin Equilenin may increase the hypokalemic activities of Torasemide. Experimental Equilin Equilin may increase the hypokalemic activities of Torasemide. Approved Esmolol The risk or severity of adverse effects can be increased when Esmolol is combined with Torasemide. Approved Estrone Estrone may increase the hypokalemic activities of Torasemide. Approved Estrone sulfate Estrone sulfate may increase the hypokalemic activities of Torasemide. Approved Etacrynic acid The risk or severity of adverse effects can be increased when Torasemide is combined with Etacrynic acid. Approved, Investigational Etanercept The therapeutic efficacy of Torasemide can be decreased when used in combination with Etanercept. Approved, Investigational Ethenzamide The therapeutic efficacy of Torasemide can be decreased when used in combination with Ethenzamide. Experimental Ethylmorphine The risk or severity of adverse effects can be increased when Ethylmorphine is combined with Torasemide. Approved, Illicit Etodolac The therapeutic efficacy of Torasemide can be decreased when used in combination with Etodolac. Approved, Investigational, Vet Approved Etofenamate The therapeutic efficacy of Torasemide can be decreased when used in combination with Etofenamate. Approved, Investigational Etoricoxib The therapeutic efficacy of Torasemide can be decreased when used in combination with Etoricoxib. Approved, Investigational Etorphine The risk or severity of adverse effects can be increased when Etorphine is combined with Torasemide. Illicit, Vet Approved Etravirine The metabolism of Torasemide can be decreased when combined with Etravirine. Approved Evening primrose oil The therapeutic efficacy of Torasemide can be decreased when used in combination with Evening primrose oil. Approved, Investigational Exenatide The therapeutic efficacy of Exenatide can be decreased when used in combination with Torasemide. Approved, Investigational Exisulind The therapeutic efficacy of Torasemide can be decreased when used in combination with Exisulind. Investigational Felbinac The therapeutic efficacy of Torasemide can be decreased when used in combination with Felbinac. Experimental Felodipine The metabolism of Torasemide can be decreased when combined with Felodipine. Approved, Investigational Fenbufen The therapeutic efficacy of Torasemide can be decreased when used in combination with Fenbufen. Approved Fenoldopam Torasemide may increase the hypotensive activities of Fenoldopam. Approved Fenoprofen The therapeutic efficacy of Torasemide can be decreased when used in combination with Fenoprofen. Approved Fenoterol Fenoterol may increase the hypokalemic activities of Torasemide. Approved, Investigational Fentanyl The risk or severity of adverse effects can be increased when Fentanyl is combined with Torasemide. Approved, Illicit, Investigational, Vet Approved Fentiazac The therapeutic efficacy of Torasemide can be decreased when used in combination with Fentiazac. Experimental Feprazone The therapeutic efficacy of Torasemide can be decreased when used in combination with Feprazone. Experimental Ferulic acid The therapeutic efficacy of Torasemide can be decreased when used in combination with Ferulic acid. Experimental Fimasartan The risk or severity of adverse effects can be increased when Fimasartan is combined with Torasemide. Approved, Investigational Floctafenine The therapeutic efficacy of Torasemide can be decreased when used in combination with Floctafenine. Approved, Withdrawn Floxuridine The metabolism of Torasemide can be decreased when combined with Floxuridine. Approved Fluasterone Fluasterone may increase the hypokalemic activities of Torasemide. Investigational Fluconazole The metabolism of Torasemide can be decreased when combined with Fluconazole. Approved, Investigational Fludrocortisone Fludrocortisone may increase the hypokalemic activities of Torasemide. Approved, Investigational Flumethasone Flumethasone may increase the hypokalemic activities of Torasemide. Approved, Vet Approved Flunisolide Flunisolide may increase the hypokalemic activities of Torasemide. Approved, Investigational Flunixin The therapeutic efficacy of Torasemide can be decreased when used in combination with Flunixin. Vet Approved Flunoxaprofen The therapeutic efficacy of Torasemide can be decreased when used in combination with Flunoxaprofen. Experimental Fluocinolone Acetonide Fluocinolone Acetonide may increase the hypokalemic activities of Torasemide. Approved, Investigational, Vet Approved Fluocinonide Fluocinonide may increase the hypokalemic activities of Torasemide. Approved, Investigational Fluocortolone Fluocortolone may increase the hypokalemic activities of Torasemide. Approved, Withdrawn Fluorometholone Fluorometholone may increase the hypokalemic activities of Torasemide. Approved, Investigational Fluorouracil The metabolism of Torasemide can be decreased when combined with Fluorouracil. Approved Fluprednidene Fluprednidene may increase the hypokalemic activities of Torasemide. Approved, Withdrawn Fluprednisolone Fluprednisolone may increase the hypokalemic activities of Torasemide. Approved Flurandrenolide Flurandrenolide may increase the hypokalemic activities of Torasemide. Approved Flurbiprofen The therapeutic efficacy of Torasemide can be decreased when used in combination with Flurbiprofen. Approved, Investigational Fluticasone furoate Fluticasone furoate may increase the hypokalemic activities of Torasemide. Approved Fluticasone propionate Fluticasone propionate may increase the hypokalemic activities of Torasemide. Approved Fluvastatin The metabolism of Torasemide can be decreased when combined with Fluvastatin. Approved Fluvoxamine The metabolism of Torasemide can be decreased when combined with Fluvoxamine. Approved, Investigational Formestane Formestane may increase the hypokalemic activities of Torasemide. Approved, Investigational, Withdrawn Formoterol Formoterol may increase the hypokalemic activities of Torasemide. Approved, Investigational Foscarnet Torasemide may decrease the excretion rate of Foscarnet which could result in a higher serum level. Approved Fosinopril Torasemide may increase the hypotensive activities of Fosinopril. Approved Fosphenytoin Fosphenytoin may decrease the diuretic activities of Torasemide. Approved, Investigational Framycetin The serum concentration of Framycetin can be increased when it is combined with Torasemide. Approved Furazolidone Furazolidone may increase the hypotensive activities of Torasemide. Approved, Investigational, Vet Approved Furosemide The risk or severity of adverse effects can be increased when Torasemide is combined with Furosemide. Approved, Vet Approved Gallamine Torasemide may decrease the neuromuscular blocking activities of Gallamine. Experimental Gallamine Triethiodide Torasemide may decrease the neuromuscular blocking activities of Gallamine Triethiodide. Approved Gemfibrozil The metabolism of Torasemide can be decreased when combined with Gemfibrozil. Approved Geneticin The serum concentration of Geneticin can be increased when it is combined with Torasemide. Experimental Gentamicin The serum concentration of Gentamicin can be increased when it is combined with Torasemide. Approved, Vet Approved GENTAMICIN C1A The serum concentration of GENTAMICIN C1A can be increased when it is combined with Torasemide. Experimental Gitoformate The risk or severity of adverse effects can be increased when Torasemide is combined with Gitoformate. Experimental Glibornuride The therapeutic efficacy of Glibornuride can be decreased when used in combination with Torasemide. Investigational, Withdrawn Gliclazide The therapeutic efficacy of Gliclazide can be decreased when used in combination with Torasemide. Approved Glimepiride The therapeutic efficacy of Glimepiride can be decreased when used in combination with Torasemide. Approved Glipizide The therapeutic efficacy of Glipizide can be decreased when used in combination with Torasemide. Approved, Investigational Gliquidone The therapeutic efficacy of Gliquidone can be decreased when used in combination with Torasemide. Approved, Investigational Glyburide The therapeutic efficacy of Glyburide can be decreased when used in combination with Torasemide. Approved GPX-150 The serum concentration of GPX-150 can be increased when it is combined with Torasemide. Investigational Guacetisal The therapeutic efficacy of Torasemide can be decreased when used in combination with Guacetisal. Experimental Guanabenz Torasemide may increase the hypotensive activities of Guanabenz. Approved, Investigational Guanadrel Torasemide may increase the hypotensive activities of Guanadrel. Approved Guanazodine Torasemide may increase the hypotensive activities of Guanazodine. Experimental Guanethidine Torasemide may increase the hypotensive activities of Guanethidine. Approved Guanfacine Guanfacine may increase the hypotensive activities of Torasemide. Approved, Investigational Guanoclor Torasemide may increase the hypotensive activities of Guanoclor. Experimental Guanoxabenz Torasemide may increase the hypotensive activities of Guanoxabenz. Experimental Guanoxan Torasemide may increase the hypotensive activities of Guanoxan. Experimental Gusperimus The therapeutic efficacy of Gusperimus can be decreased when used in combination with Torasemide. Investigational Halcinonide Halcinonide may increase the hypokalemic activities of Torasemide. Approved, Investigational, Withdrawn Halothane The risk or severity of adverse effects can be increased when Halothane is combined with Torasemide. Approved, Vet Approved Harmaline Harmaline may increase the hypotensive activities of Torasemide. Experimental HE3286 HE3286 may increase the hypokalemic activities of Torasemide. Investigational Hemoglobin crosfumaril The therapeutic efficacy of Torasemide can be decreased when used in combination with Hemoglobin crosfumaril. Experimental Heroin The risk or severity of adverse effects can be increased when Heroin is combined with Torasemide. Approved, Illicit, Investigational Hexamethonium Torasemide may increase the hypotensive activities of Hexamethonium. Experimental Hexobarbital Hexobarbital may increase the hypotensive activities of Torasemide. Approved Higenamine The therapeutic efficacy of Torasemide can be decreased when used in combination with Higenamine. Investigational Hydracarbazine Hydracarbazine may increase the hypotensive activities of Torasemide. Experimental Hydralazine Hydralazine may increase the hypotensive activities of Torasemide. Approved Hydrochlorothiazide Torasemide may increase the hypotensive activities of Hydrochlorothiazide. Approved, Vet Approved Hydrocodone The risk or severity of adverse effects can be increased when Hydrocodone is combined with Torasemide. Approved, Illicit Hydrocortisone Hydrocortisone may increase the hypokalemic activities of Torasemide. Approved, Vet Approved Hydroflumethiazide Torasemide may increase the hypotensive activities of Hydroflumethiazide. Approved, Investigational Hydromorphone The risk or severity of adverse effects can be increased when Hydromorphone is combined with Torasemide. Approved, Illicit Hygromycin B The serum concentration of Hygromycin B can be increased when it is combined with Torasemide. Vet Approved Ibuprofen The therapeutic efficacy of Torasemide can be decreased when used in combination with Ibuprofen. Approved Ibuproxam The therapeutic efficacy of Torasemide can be decreased when used in combination with Ibuproxam. Withdrawn Icatibant The therapeutic efficacy of Torasemide can be decreased when used in combination with Icatibant. Approved, Investigational Idarubicin The serum concentration of Idarubicin can be increased when it is combined with Torasemide. Approved Iloprost The risk or severity of adverse effects can be increased when Iloprost is combined with Torasemide. Approved, Investigational Imidapril Torasemide may increase the hypotensive activities of Imidapril. Investigational Imidazole salicylate The therapeutic efficacy of Torasemide can be decreased when used in combination with Imidazole salicylate. Experimental Imipramine The risk or severity of adverse effects can be increased when Imipramine is combined with Torasemide. Approved Indacaterol Indacaterol may increase the hypokalemic activities of Torasemide. Approved Indapamide Torasemide may increase the hypotensive activities of Indapamide. Approved Indenolol Torasemide may increase the hypotensive activities of Indenolol. Withdrawn Indinavir The metabolism of Torasemide can be decreased when combined with Indinavir. Approved Indobufen The therapeutic efficacy of Torasemide can be decreased when used in combination with Indobufen. Investigational Indomethacin The therapeutic efficacy of Torasemide can be decreased when used in combination with Indomethacin. Approved, Investigational Indoprofen The therapeutic efficacy of Torasemide can be decreased when used in combination with Indoprofen. Withdrawn Indoramin Indoramin may increase the hypotensive activities of Torasemide. Withdrawn Insulin Aspart The therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Torasemide. Approved Insulin Detemir The therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Torasemide. Approved Insulin Glargine The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Torasemide. Approved Insulin Glulisine The therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Torasemide. Approved Insulin Human The therapeutic efficacy of Insulin Human can be decreased when used in combination with Torasemide. Approved, Investigational Insulin Lispro The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Torasemide. Approved Insulin Pork The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Torasemide. Approved Iproclozide Iproclozide may increase the hypotensive activities of Torasemide. Withdrawn Iproniazid Iproniazid may increase the hypotensive activities of Torasemide. Withdrawn Irbesartan The metabolism of Torasemide can be decreased when combined with Irbesartan. Approved, Investigational Isepamicin The serum concentration of Isepamicin can be increased when it is combined with Torasemide. Experimental Isocarboxazid Isocarboxazid may increase the hypotensive activities of Torasemide. Approved Isoetarine Isoetarine may increase the hypokalemic activities of Torasemide. Approved Isoflurane The risk or severity of adverse effects can be increased when Isoflurane is combined with Torasemide. Approved, Vet Approved Isoprenaline Isoprenaline may increase the hypokalemic activities of Torasemide. Approved, Investigational Isosorbide Dinitrate The risk or severity of adverse effects can be increased when Torasemide is combined with Isosorbide Dinitrate. Approved, Investigational Isosorbide Mononitrate The risk or severity of adverse effects can be increased when Torasemide is combined with Isosorbide Mononitrate. Approved Isoxicam The therapeutic efficacy of Torasemide can be decreased when used in combination with Isoxicam. Withdrawn Isoxsuprine The risk or severity of adverse effects can be increased when Torasemide is combined with Isoxsuprine. Approved, Withdrawn Isradipine Torasemide may increase the hypotensive activities of Isradipine. Approved, Investigational Istaroxime Istaroxime may increase the hypokalemic activities of Torasemide. Investigational Ivabradine Torasemide may increase the arrhythmogenic activities of Ivabradine. Approved Kanamycin The serum concentration of Kanamycin can be increased when it is combined with Torasemide. Approved, Investigational, Vet Approved Kebuzone The therapeutic efficacy of Torasemide can be decreased when used in combination with Kebuzone. Experimental Ketanserin Ketanserin may increase the hypotensive activities of Torasemide. Investigational Ketobemidone The risk or severity of adverse effects can be increased when Ketobemidone is combined with Torasemide. Approved, Investigational Ketoconazole The metabolism of Torasemide can be decreased when combined with Ketoconazole. Approved, Investigational Ketoprofen The therapeutic efficacy of Torasemide can be decreased when used in combination with Ketoprofen. Approved, Vet Approved Ketorolac The therapeutic efficacy of Torasemide can be decreased when used in combination with Ketorolac. Approved Labetalol Torasemide may increase the hypotensive activities of Labetalol. Approved Lacidipine Torasemide may increase the hypotensive activities of Lacidipine. Approved, Investigational Lanatoside C The risk or severity of adverse effects can be increased when Torasemide is combined with Lanatoside C. Experimental Lapatinib The metabolism of Torasemide can be decreased when combined with Lapatinib. Approved, Investigational Latanoprost Torasemide may increase the hypotensive activities of Latanoprost. Approved, Investigational Leflunomide The therapeutic efficacy of Torasemide can be decreased when used in combination with Leflunomide. Approved, Investigational Lercanidipine Torasemide may increase the hypotensive activities of Lercanidipine. Approved, Investigational Levobunolol The risk or severity of adverse effects can be increased when Torasemide is combined with Levobunolol. Approved Levobupivacaine The risk or severity of adverse effects can be increased when Levobupivacaine is combined with Torasemide. Approved, Investigational Levodopa Torasemide may increase the orthostatic hypotensive activities of Levodopa. Approved Levomethadyl Acetate The risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Torasemide. Approved, Investigational Levorphanol The risk or severity of adverse effects can be increased when Levorphanol is combined with Torasemide. Approved Levosalbutamol Levosalbutamol may increase the hypokalemic activities of Torasemide. Approved, Investigational Levosimendan The risk or severity of adverse effects can be increased when Levosimendan is combined with Torasemide. Approved, Investigational Licorice The risk or severity of hypokalemia can be increased when Licorice is combined with Torasemide. Approved Linagliptin The therapeutic efficacy of Linagliptin can be decreased when used in combination with Torasemide. Approved Linsidomine Torasemide may increase the hypotensive activities of Linsidomine. Experimental Liraglutide The therapeutic efficacy of Liraglutide can be decreased when used in combination with Torasemide. Approved Lisinopril Torasemide may increase the hypotensive activities of Lisinopril. Approved, Investigational Lisofylline The therapeutic efficacy of Torasemide can be decreased when used in combination with Lisofylline. Investigational Lithium The serum concentration of Lithium can be decreased when it is combined with Torasemide. Approved Lobeglitazone The metabolism of Torasemide can be decreased when combined with Lobeglitazone. Approved, Investigational Lofentanil The risk or severity of adverse effects can be increased when Lofentanil is combined with Torasemide. Illicit Lofexidine Torasemide may increase the hypotensive activities of Lofexidine. Approved, Investigational Lonazolac The therapeutic efficacy of Torasemide can be decreased when used in combination with Lonazolac. Experimental Lornoxicam The therapeutic efficacy of Torasemide can be decreased when used in combination with Lornoxicam. Approved, Investigational Losartan The metabolism of Torasemide can be decreased when combined with Losartan. Approved Loteprednol Loteprednol may increase the hypokalemic activities of Torasemide. Approved Lovastatin The metabolism of Torasemide can be decreased when combined with Lovastatin. Approved, Investigational Loxoprofen The therapeutic efficacy of Torasemide can be decreased when used in combination with Loxoprofen. Approved, Investigational Lumacaftor The serum concentration of Torasemide can be increased when it is combined with Lumacaftor. Approved Lumiracoxib The therapeutic efficacy of Torasemide can be decreased when used in combination with Lumiracoxib. Approved, Investigational Macitentan Torasemide may increase the hypotensive activities of Macitentan. Approved Magnesium salicylate The therapeutic efficacy of Torasemide can be decreased when used in combination with Magnesium salicylate. Approved Manidipine Torasemide may increase the hypotensive activities of Manidipine. Approved, Investigational Mannitol The risk or severity of adverse effects can be increased when Torasemide is combined with Mannitol. Approved, Investigational Masoprocol The therapeutic efficacy of Torasemide can be decreased when used in combination with Masoprocol. Approved, Investigational ME-609 ME-609 may increase the hypokalemic activities of Torasemide. Investigational Mebanazine Mebanazine may increase the hypotensive activities of Torasemide. Withdrawn Mecamylamine Mecamylamine may increase the hypotensive activities of Torasemide. Approved, Investigational Meclofenamic acid The therapeutic efficacy of Torasemide can be decreased when used in combination with Meclofenamic acid. Approved, Vet Approved Medrysone Medrysone may increase the hypokalemic activities of Torasemide. Approved Mefenamic acid The therapeutic efficacy of Torasemide can be decreased when used in combination with Mefenamic acid. Approved Melengestrol Melengestrol may increase the hypokalemic activities of Torasemide. Vet Approved Meloxicam The therapeutic efficacy of Torasemide can be decreased when used in combination with Meloxicam. Approved, Vet Approved Meptazinol The risk or severity of adverse effects can be increased when Meptazinol is combined with Torasemide. Experimental Mesalazine The therapeutic efficacy of Torasemide can be decreased when used in combination with Mesalazine. Approved Metamizole The therapeutic efficacy of Torasemide can be decreased when used in combination with Metamizole. Approved, Investigational, Withdrawn Metformin The therapeutic efficacy of Metformin can be decreased when used in combination with Torasemide. Approved Methadone The risk or severity of adverse effects can be increased when Methadone is combined with Torasemide. Approved Methadyl Acetate The risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Torasemide. Approved, Illicit Methazolamide The risk or severity of adverse effects can be increased when Torasemide is combined with Methazolamide. Approved Methohexital Methohexital may increase the hypotensive activities of Torasemide. Approved Methoserpidine Torasemide may increase the hypotensive activities of Methoserpidine. Experimental Methotrexate The therapeutic efficacy of Torasemide can be decreased when used in combination with Methotrexate. Approved Methyclothiazide The risk or severity of adverse effects can be increased when Torasemide is combined with Methyclothiazide. Approved Methyl salicylate The therapeutic efficacy of Torasemide can be decreased when used in combination with Methyl salicylate. Approved, Vet Approved Methyldopa Torasemide may increase the hypotensive activities of Methyldopa. Approved Methylene blue Methylene blue may increase the hypotensive activities of Torasemide. Approved, Investigational Methylphenidate Methylphenidate may decrease the antihypertensive activities of Torasemide. Approved, Investigational Methylphenobarbital Methylphenobarbital may increase the hypotensive activities of Torasemide. Approved Methylprednisolone Methylprednisolone may increase the hypokalemic activities of Torasemide. Approved, Vet Approved Metildigoxin The risk or severity of adverse effects can be increased when Torasemide is combined with Metildigoxin. Experimental Metipranolol Torasemide may increase the hypotensive activities of Metipranolol. Approved Metocurine Torasemide may decrease the neuromuscular blocking activities of Metocurine. Approved Metocurine Iodide Torasemide may decrease the neuromuscular blocking activities of Metocurine Iodide. Approved, Withdrawn Metolazone Torasemide may increase the hypotensive activities of Metolazone. Approved Metoprolol Torasemide may increase the hypotensive activities of Metoprolol. Approved, Investigational Metrizamide The serum concentration of Metrizamide can be increased when it is combined with Torasemide. Approved Metyrosine Torasemide may increase the hypotensive activities of Metyrosine. Approved Mibefradil Torasemide may increase the hypotensive activities of Mibefradil. Investigational, Withdrawn Micronomicin The serum concentration of Micronomicin can be increased when it is combined with Torasemide. Experimental Midostaurin The metabolism of Torasemide can be decreased when combined with Midostaurin. Approved, Investigational Mifepristone The serum concentration of Torasemide can be increased when it is combined with Mifepristone. Approved, Investigational Miglitol The therapeutic efficacy of Miglitol can be decreased when used in combination with Torasemide. Approved Miglustat The therapeutic efficacy of Miglustat can be decreased when used in combination with Torasemide. Approved Minaprine Minaprine may increase the hypotensive activities of Torasemide. Approved Minoxidil Minoxidil may increase the hypotensive activities of Torasemide. Approved, Investigational Mirodenafil Mirodenafil may increase the antihypertensive activities of Torasemide. Investigational Mitiglinide The therapeutic efficacy of Mitiglinide can be decreased when used in combination with Torasemide. Approved, Investigational Mivacurium Torasemide may decrease the neuromuscular blocking activities of Mivacurium. Approved Mizoribine The therapeutic efficacy of Torasemide can be decreased when used in combination with Mizoribine. Investigational Moclobemide Moclobemide may increase the hypotensive activities of Torasemide. Approved, Investigational Moexipril Torasemide may increase the hypotensive activities of Moexipril. Approved Mofebutazone The therapeutic efficacy of Torasemide can be decreased when used in combination with Mofebutazone. Experimental Molsidomine Molsidomine may increase the hypotensive activities of Torasemide. Approved, Investigational Mometasone Mometasone may increase the hypokalemic activities of Torasemide. Approved, Vet Approved Morphine The risk or severity of adverse effects can be increased when Morphine is combined with Torasemide. Approved, Investigational Moxonidine Moxonidine may increase the hypotensive activities of Torasemide. Approved, Investigational Muzolimine Torasemide may increase the hypotensive activities of Muzolimine. Experimental Mycophenolate mofetil The therapeutic efficacy of Torasemide can be decreased when used in combination with Mycophenolate mofetil. Approved, Investigational Mycophenolic acid The therapeutic efficacy of Torasemide can be decreased when used in combination with Mycophenolic acid. Approved Nabilone The risk or severity of adverse effects can be increased when Nabilone is combined with Torasemide. Approved, Investigational Nabumetone The therapeutic efficacy of Torasemide can be decreased when used in combination with Nabumetone. Approved Nadolol Torasemide may increase the hypotensive activities of Nadolol. Approved Nafamostat The therapeutic efficacy of Torasemide can be decreased when used in combination with Nafamostat. Approved, Investigational Naftifine The therapeutic efficacy of Torasemide can be decreased when used in combination with Naftifine. Approved Naftopidil Torasemide may increase the hypotensive activities of Naftopidil. Investigational Nalbuphine The risk or severity of adverse effects can be increased when Nalbuphine is combined with Torasemide. Approved Naproxen The therapeutic efficacy of Torasemide can be decreased when used in combination with Naproxen. Approved, Vet Approved Nateglinide The therapeutic efficacy of Nateglinide can be decreased when used in combination with Torasemide. Approved, Investigational NCX 1022 NCX 1022 may increase the hypokalemic activities of Torasemide. Investigational Neamine The serum concentration of Neamine can be increased when it is combined with Torasemide. Experimental Nebivolol Torasemide may increase the hypotensive activities of Nebivolol. Approved, Investigational Neomycin The serum concentration of Neomycin can be increased when it is combined with Torasemide. Approved, Vet Approved Neosaxitoxin Torasemide may decrease the neuromuscular blocking activities of Neosaxitoxin. Investigational Nepafenac The therapeutic efficacy of Torasemide can be decreased when used in combination with Nepafenac. Approved, Investigational Nesiritide The risk or severity of adverse effects can be increased when Torasemide is combined with Nesiritide. Approved, Investigational Netilmicin The serum concentration of Netilmicin can be increased when it is combined with Torasemide. Approved, Investigational Nialamide Nialamide may increase the hypotensive activities of Torasemide. Withdrawn Nicardipine The metabolism of Torasemide can be decreased when combined with Nicardipine. Approved, Investigational Nicomorphine The risk or severity of adverse effects can be increased when Nicomorphine is combined with Torasemide. Experimental Nicorandil Nicorandil may increase the hypotensive activities of Torasemide. Approved, Investigational Nifedipine The risk or severity of adverse effects can be increased when Torasemide is combined with Nifedipine. Approved Nifenazone The therapeutic efficacy of Torasemide can be decreased when used in combination with Nifenazone. Experimental Niflumic Acid The therapeutic efficacy of Torasemide can be decreased when used in combination with Niflumic Acid. Approved Niguldipine Torasemide may increase the hypotensive activities of Niguldipine. Experimental Nilotinib The metabolism of Torasemide can be decreased when combined with Nilotinib. Approved, Investigational Nilvadipine Torasemide may increase the hypotensive activities of Nilvadipine. Approved, Investigational Nimesulide The therapeutic efficacy of Torasemide can be decreased when used in combination with Nimesulide. Approved, Investigational, Withdrawn Nimodipine Torasemide may increase the hypotensive activities of Nimodipine. Approved, Investigational Nisoldipine Torasemide may increase the hypotensive activities of Nisoldipine. Approved Nitrendipine Torasemide may increase the hypotensive activities of Nitrendipine. Approved, Investigational Nitric Oxide The risk or severity of adverse effects can be increased when Nitric Oxide is combined with Torasemide. Approved Nitroaspirin The therapeutic efficacy of Torasemide can be decreased when used in combination with Nitroaspirin. Investigational Nitroglycerin The risk or severity of adverse effects can be increased when Torasemide is combined with Nitroglycerin. Approved, Investigational Nitroprusside Nitroprusside may increase the hypotensive activities of Torasemide. Approved, Investigational Nitrous acid The risk or severity of adverse effects can be increased when Nitrous acid is combined with Torasemide. Approved, Investigational Norepinephrine Norepinephrine may increase the hypokalemic activities of Torasemide. Approved Normethadone The risk or severity of adverse effects can be increased when Normethadone is combined with Torasemide. Approved, Illicit Obinutuzumab Torasemide may increase the hypotensive activities of Obinutuzumab. Approved, Investigational Octamoxin Octamoxin may increase the hypotensive activities of Torasemide. Withdrawn Oleandrin The risk or severity of adverse effects can be increased when Torasemide is combined with Oleandrin. Experimental, Investigational Oleoyl-estrone Oleoyl-estrone may increase the hypokalemic activities of Torasemide. Investigational Olmesartan Torasemide may increase the hypotensive activities of Olmesartan. Approved, Investigational Olodaterol Olodaterol may increase the hypokalemic activities of Torasemide. Approved Olopatadine The therapeutic efficacy of Torasemide can be decreased when used in combination with Olopatadine. Approved Olsalazine The therapeutic efficacy of Torasemide can be decreased when used in combination with Olsalazine. Approved Omapatrilat Torasemide may increase the hypotensive activities of Omapatrilat. Investigational Omeprazole The metabolism of Torasemide can be decreased when combined with Omeprazole. Approved, Investigational, Vet Approved Opium The risk or severity of adverse effects can be increased when Opium is combined with Torasemide. Approved, Illicit Orciprenaline Orciprenaline may increase the hypokalemic activities of Torasemide. Approved Orgotein The therapeutic efficacy of Torasemide can be decreased when used in combination with Orgotein. Vet Approved Ouabain The risk or severity of adverse effects can be increased when Torasemide is combined with Ouabain. Approved Oxaprozin The therapeutic efficacy of Torasemide can be decreased when used in combination with Oxaprozin. Approved Oxprenolol Torasemide may increase the hypotensive activities of Oxprenolol. Approved Oxycodone The risk or severity of adverse effects can be increased when Oxycodone is combined with Torasemide. Approved, Illicit, Investigational Oxymorphone The risk or severity of adverse effects can be increased when Oxymorphone is combined with Torasemide. Approved, Investigational, Vet Approved Oxyphenbutazone The therapeutic efficacy of Torasemide can be decreased when used in combination with Oxyphenbutazone. Approved, Withdrawn Paclitaxel The risk or severity of adverse effects can be increased when Paclitaxel is combined with Torasemide. Approved, Vet Approved Pancuronium Torasemide may decrease the neuromuscular blocking activities of Pancuronium. Approved Papaverine The risk or severity of adverse effects can be increased when Torasemide is combined with Papaverine. Approved, Investigational Paramethasone Paramethasone may increase the hypokalemic activities of Torasemide. Approved Parecoxib The therapeutic efficacy of Torasemide can be decreased when used in combination with Parecoxib. Approved Pargyline Pargyline may increase the hypotensive activities of Torasemide. Approved Paromomycin The serum concentration of Paromomycin can be increased when it is combined with Torasemide. Approved, Investigational Parthenolide The therapeutic efficacy of Torasemide can be decreased when used in combination with Parthenolide. Approved, Investigational Penbutolol Torasemide may increase the hypotensive activities of Penbutolol. Approved, Investigational Pentazocine The risk or severity of adverse effects can be increased when Pentazocine is combined with Torasemide. Approved, Vet Approved Pentobarbital Pentobarbital may increase the hypotensive activities of Torasemide. Approved, Investigational, Vet Approved Pentolinium Torasemide may increase the hypotensive activities of Pentolinium. Approved Pentoxifylline Pentoxifylline may increase the hypotensive activities of Torasemide. Approved, Investigational Perindopril Torasemide may increase the hypotensive activities of Perindopril. Approved Peruvoside The risk or severity of adverse effects can be increased when Torasemide is combined with Peruvoside. Experimental Pethidine The risk or severity of adverse effects can be increased when Pethidine is combined with Torasemide. Approved Phenazocine The risk or severity of adverse effects can be increased when Phenazocine is combined with Torasemide. Experimental Phenelzine Phenelzine may increase the hypotensive activities of Torasemide. Approved Phenformin The therapeutic efficacy of Phenformin can be decreased when used in combination with Torasemide. Approved, Investigational, Withdrawn Pheniprazine Pheniprazine may increase the hypotensive activities of Torasemide. Withdrawn Phenobarbital The metabolism of Torasemide can be increased when combined with Phenobarbital. Approved, Investigational Phenoperidine The risk or severity of adverse effects can be increased when Phenoperidine is combined with Torasemide. Experimental Phenoxybenzamine Torasemide may increase the hypotensive activities of Phenoxybenzamine. Approved Phenoxypropazine Phenoxypropazine may increase the hypotensive activities of Torasemide. Withdrawn Phentolamine Torasemide may increase the hypotensive activities of Phentolamine. Approved Phenyl aminosalicylate The therapeutic efficacy of Torasemide can be decreased when used in combination with Phenyl aminosalicylate. Approved Phenylbutazone The therapeutic efficacy of Torasemide can be decreased when used in combination with Phenylbutazone. Approved, Vet Approved Phenylpropanolamine Phenylpropanolamine may increase the hypokalemic activities of Torasemide. Approved, Vet Approved, Withdrawn Phenytoin Phenytoin may decrease the diuretic activities of Torasemide. Approved, Vet Approved Pimecrolimus The therapeutic efficacy of Torasemide can be decreased when used in combination with Pimecrolimus. Approved, Investigational Pinacidil Pinacidil may increase the hypotensive activities of Torasemide. Approved Pindolol Torasemide may increase the hypotensive activities of Pindolol. Approved, Investigational Pioglitazone The metabolism of Torasemide can be decreased when combined with Pioglitazone. Approved, Investigational Pipamperone The risk or severity of adverse effects can be increased when Pipamperone is combined with Torasemide. Approved, Investigational Pipecuronium Torasemide may decrease the neuromuscular blocking activities of Pipecuronium. Approved Pirarubicin The serum concentration of Pirarubicin can be increased when it is combined with Torasemide. Investigational Pirbuterol Pirbuterol may increase the hypokalemic activities of Torasemide. Approved Pirfenidone The therapeutic efficacy of Torasemide can be decreased when used in combination with Pirfenidone. Approved, Investigational Piritramide The risk or severity of adverse effects can be increased when Piritramide is combined with Torasemide. Approved, Investigational Pirlindole Pirlindole may increase the hypotensive activities of Torasemide. Approved Piroxicam The therapeutic efficacy of Torasemide can be decreased when used in combination with Piroxicam. Approved, Investigational Pirprofen The therapeutic efficacy of Torasemide can be decreased when used in combination with Pirprofen. Experimental Pivhydrazine Pivhydrazine may increase the hypotensive activities of Torasemide. Withdrawn Platelet Activating Factor Torasemide may increase the hypotensive activities of Platelet Activating Factor. Experimental Plazomicin The serum concentration of Plazomicin can be increased when it is combined with Torasemide. Investigational Plicamycin The serum concentration of Plicamycin can be increased when it is combined with Torasemide. Approved, Investigational, Withdrawn Polythiazide Torasemide may increase the hypotensive activities of Polythiazide. Approved Pramipexole The risk or severity of adverse effects can be increased when Pramipexole is combined with Torasemide. Approved, Investigational Pramlintide The therapeutic efficacy of Pramlintide can be decreased when used in combination with Torasemide. Approved, Investigational Pranoprofen The therapeutic efficacy of Torasemide can be decreased when used in combination with Pranoprofen. Experimental, Investigational Prasterone Prasterone may increase the hypokalemic activities of Torasemide. Approved, Investigational, Nutraceutical Prasterone sulfate Prasterone sulfate may increase the hypokalemic activities of Torasemide. Investigational Prazosin Prazosin may increase the hypotensive activities of Torasemide. Approved Prednicarbate Prednicarbate may increase the hypokalemic activities of Torasemide. Approved, Investigational Prednisolone Prednisolone may increase the hypokalemic activities of Torasemide. Approved, Vet Approved Prednisone Prednisone may increase the hypokalemic activities of Torasemide. Approved, Vet Approved Pregnenolone Pregnenolone may increase the hypokalemic activities of Torasemide. Approved, Experimental, Investigational Primidone The metabolism of Torasemide can be increased when combined with Primidone. Approved, Vet Approved Probenecid The risk or severity of adverse effects can be increased when Probenecid is combined with Torasemide. Approved, Investigational Procarbazine Procarbazine may increase the hypotensive activities of Torasemide. Approved, Investigational Procaterol Procaterol may increase the hypokalemic activities of Torasemide. Approved, Investigational Proglumetacin The therapeutic efficacy of Torasemide can be decreased when used in combination with Proglumetacin. Experimental Propacetamol The therapeutic efficacy of Torasemide can be decreased when used in combination with Propacetamol. Approved, Investigational Propofol The risk or severity of adverse effects can be increased when Propofol is combined with Torasemide. Approved, Investigational, Vet Approved Propranolol Torasemide may increase the hypotensive activities of Propranolol. Approved, Investigational Propyphenazone The therapeutic efficacy of Torasemide can be decreased when used in combination with Propyphenazone. Experimental Proquazone The therapeutic efficacy of Torasemide can be decreased when used in combination with Proquazone. Experimental Proscillaridin The risk or severity of adverse effects can be increased when Torasemide is combined with Proscillaridin. Experimental Protokylol Protokylol may increase the hypokalemic activities of Torasemide. Approved, Vet Approved PTC299 The therapeutic efficacy of Torasemide can be decreased when used in combination with PTC299. Investigational Puromycin The serum concentration of Puromycin can be increased when it is combined with Torasemide. Experimental Pyrantel Torasemide may decrease the neuromuscular blocking activities of Pyrantel. Approved, Vet Approved Pyrimethamine The metabolism of Torasemide can be decreased when combined with Pyrimethamine. Approved, Investigational, Vet Approved Quetiapine The risk or severity of adverse effects can be increased when Torasemide is combined with Quetiapine. Approved Quinapril Torasemide may increase the hypotensive activities of Quinapril. Approved, Investigational Quinine The metabolism of Torasemide can be decreased when combined with Quinine. Approved Rabeprazole The metabolism of Torasemide can be decreased when combined with Rabeprazole. Approved, Investigational Racepinephrine Racepinephrine may increase the hypokalemic activities of Torasemide. Approved Ramipril Torasemide may increase the hypotensive activities of Ramipril. Approved Rapacuronium Torasemide may decrease the neuromuscular blocking activities of Rapacuronium. Withdrawn Rasagiline Rasagiline may increase the hypotensive activities of Torasemide. Approved Remifentanil The risk or severity of adverse effects can be increased when Remifentanil is combined with Torasemide. Approved Remikiren Remikiren may increase the hypotensive activities of Torasemide. Approved Repaglinide The therapeutic efficacy of Repaglinide can be decreased when used in combination with Torasemide. Approved, Investigational Rescinnamine Torasemide may increase the hypotensive activities of Rescinnamine. Approved Reserpine Reserpine may increase the hypotensive activities of Torasemide. Approved, Investigational Resveratrol The therapeutic efficacy of Torasemide can be decreased when used in combination with Resveratrol. Approved, Experimental, Investigational Ribostamycin The serum concentration of Ribostamycin can be increased when it is combined with Torasemide. Approved, Investigational Rifampicin The metabolism of Torasemide can be increased when combined with Rifampicin. Approved Rifapentine The metabolism of Torasemide can be increased when combined with Rifapentine. Approved, Investigational Rilmenidine Rilmenidine may increase the hypotensive activities of Torasemide. Approved, Investigational Rimexolone Rimexolone may increase the hypokalemic activities of Torasemide. Approved Riociguat Torasemide may increase the hypotensive activities of Riociguat. Approved Risperidone The risk or severity of adverse effects can be increased when Torasemide is combined with Risperidone. Approved, Investigational Ritodrine Ritodrine may increase the hypokalemic activities of Torasemide. Approved, Investigational Rituximab Torasemide may increase the hypotensive activities of Rituximab. Approved Rocuronium Torasemide may decrease the neuromuscular blocking activities of Rocuronium. Approved Rofecoxib The therapeutic efficacy of Torasemide can be decreased when used in combination with Rofecoxib. Approved, Investigational, Withdrawn Ropinirole The risk or severity of adverse effects can be increased when Ropinirole is combined with Torasemide. Approved, Investigational Ropivacaine The risk or severity of adverse effects can be increased when Ropivacaine is combined with Torasemide. Approved Rosiglitazone The metabolism of Torasemide can be decreased when combined with Rosiglitazone. Approved, Investigational Rotigotine The risk or severity of adverse effects can be increased when Rotigotine is combined with Torasemide. Approved Rucaparib The metabolism of Torasemide can be decreased when combined with Rucaparib. Approved, Investigational Sabarubicin The serum concentration of Sabarubicin can be increased when it is combined with Torasemide. Investigational Sacubitril The risk or severity of adverse effects can be increased when Sacubitril is combined with Torasemide. Approved Safrazine Safrazine may increase the hypotensive activities of Torasemide. Withdrawn Salbutamol Salbutamol may increase the hypokalemic activities of Torasemide. Approved, Vet Approved Salicylamide The therapeutic efficacy of Torasemide can be decreased when used in combination with Salicylamide. Approved Salicylic acid The therapeutic efficacy of Torasemide can be decreased when used in combination with Salicylic acid. Approved, Investigational, Vet Approved Salmeterol Salmeterol may increase the hypokalemic activities of Torasemide. Approved Salsalate The therapeutic efficacy of Torasemide can be decreased when used in combination with Salsalate. Approved Saprisartan Torasemide may increase the hypotensive activities of Saprisartan. Experimental Saxagliptin The therapeutic efficacy of Saxagliptin can be decreased when used in combination with Torasemide. Approved Secobarbital The metabolism of Torasemide can be increased when combined with Secobarbital. Approved, Vet Approved Selegiline Selegiline may increase the hypotensive activities of Torasemide. Approved, Investigational, Vet Approved Selexipag Torasemide may increase the hypotensive activities of Selexipag. Approved Semapimod The therapeutic efficacy of Torasemide can be decreased when used in combination with Semapimod. Investigational Seratrodast The therapeutic efficacy of Torasemide can be decreased when used in combination with Seratrodast. Approved Serrapeptase The therapeutic efficacy of Torasemide can be decreased when used in combination with Serrapeptase. Investigational Sevoflurane The risk or severity of adverse effects can be increased when Sevoflurane is combined with Torasemide. Approved, Vet Approved Sildenafil Sildenafil may increase the antihypertensive activities of Torasemide. Approved, Investigational Sisomicin The serum concentration of Sisomicin can be increased when it is combined with Torasemide. Investigational Sitagliptin The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Torasemide. Approved, Investigational Sitaxentan Torasemide may increase the hypotensive activities of Sitaxentan. Approved, Investigational, Withdrawn Sodium phosphate Torasemide may increase the nephrotoxic activities of Sodium phosphate. Approved Sorafenib The metabolism of Torasemide can be decreased when combined with Sorafenib. Approved, Investigational Sotagliflozin The therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Torasemide. Investigational Sotalol The risk or severity of adverse effects can be increased when Torasemide is combined with Sotalol. Approved SP1049C The serum concentration of SP1049C can be increased when it is combined with Torasemide. Investigational Spectinomycin The serum concentration of Spectinomycin can be increased when it is combined with Torasemide. Approved, Investigational, Vet Approved Spirapril Torasemide may increase the hypotensive activities of Spirapril. Approved Spironolactone The risk or severity of adverse effects can be increased when Torasemide is combined with Spironolactone. Approved SRT501 The therapeutic efficacy of Torasemide can be decreased when used in combination with SRT501. Investigational Streptokinase The risk or severity of adverse effects can be increased when Streptokinase is combined with Torasemide. Approved, Investigational Streptomycin The serum concentration of Streptomycin can be increased when it is combined with Torasemide. Approved, Vet Approved Streptozocin The serum concentration of Streptozocin can be increased when it is combined with Torasemide. Approved, Investigational Succinylcholine Torasemide may decrease the neuromuscular blocking activities of Succinylcholine. Approved Sufentanil The risk or severity of adverse effects can be increased when Sufentanil is combined with Torasemide. Approved, Investigational Sulfadiazine The metabolism of Torasemide can be decreased when combined with Sulfadiazine. Approved, Investigational, Vet Approved Sulfamethoxazole The metabolism of Torasemide can be decreased when combined with Sulfamethoxazole. Approved Sulfasalazine The therapeutic efficacy of Torasemide can be decreased when used in combination with Sulfasalazine. Approved Sulfisoxazole The metabolism of Torasemide can be decreased when combined with Sulfisoxazole. Approved, Vet Approved Sulindac The therapeutic efficacy of Torasemide can be decreased when used in combination with Sulindac. Approved, Investigational Sulodexide The therapeutic efficacy of Sulodexide can be decreased when used in combination with Torasemide. Approved, Investigational Sulpiride The risk or severity of adverse effects can be increased when Torasemide is combined with Sulpiride. Approved, Investigational Suprofen The therapeutic efficacy of Torasemide can be decreased when used in combination with Suprofen. Approved, Withdrawn Suxibuzone The therapeutic efficacy of Torasemide can be decreased when used in combination with Suxibuzone. Experimental Tadalafil Tadalafil may increase the antihypertensive activities of Torasemide. Approved, Investigational Talinolol Torasemide may increase the hypotensive activities of Talinolol. Investigational Tamoxifen The metabolism of Torasemide can be decreased when combined with Tamoxifen. Approved Tamsulosin The risk or severity of adverse effects can be increased when Tamsulosin is combined with Torasemide. Approved, Investigational Tapentadol The risk or severity of adverse effects can be increased when Tapentadol is combined with Torasemide. Approved Tarenflurbil The therapeutic efficacy of Torasemide can be decreased when used in combination with Tarenflurbil. Investigational Telmisartan Torasemide may increase the hypotensive activities of Telmisartan. Approved, Investigational Temocapril Torasemide may increase the hypotensive activities of Temocapril. Experimental, Investigational Tenidap The therapeutic efficacy of Torasemide can be decreased when used in combination with Tenidap. Experimental Tenoxicam The therapeutic efficacy of Torasemide can be decreased when used in combination with Tenoxicam. Approved Tepoxalin The therapeutic efficacy of Torasemide can be decreased when used in combination with Tepoxalin. Vet Approved Terazosin The risk or severity of adverse effects can be increased when Torasemide is combined with Terazosin. Approved Terbutaline Terbutaline may increase the hypokalemic activities of Torasemide. Approved Teriflunomide The therapeutic efficacy of Torasemide can be decreased when used in combination with Teriflunomide. Approved Terlipressin Torasemide may increase the hypotensive activities of Terlipressin. Approved, Investigational Tetrahydropalmatine Torasemide may increase the hypotensive activities of Tetrahydropalmatine. Investigational Thalidomide The risk or severity of adverse effects can be increased when Thalidomide is combined with Torasemide. Approved, Investigational, Withdrawn Theodrenaline Torasemide may increase the hypotensive activities of Theodrenaline. Investigational Thiamylal Thiamylal may increase the hypotensive activities of Torasemide. Approved, Vet Approved Thiopental Thiopental may increase the hypotensive activities of Torasemide. Approved, Vet Approved Thioridazine The risk or severity of adverse effects can be increased when Thioridazine is combined with Torasemide. Approved, Withdrawn Tiaprofenic acid The therapeutic efficacy of Torasemide can be decreased when used in combination with Tiaprofenic acid. Approved Tibolone Torasemide may increase the hypotensive activities of Tibolone. Approved, Investigational Ticagrelor The metabolism of Torasemide can be decreased when combined with Ticagrelor. Approved Ticlopidine The metabolism of Torasemide can be decreased when combined with Ticlopidine. Approved Ticrynafen Torasemide may increase the hypotensive activities of Ticrynafen. Withdrawn Tilidine The risk or severity of adverse effects can be increased when Tilidine is combined with Torasemide. Experimental Timolol Torasemide may increase the hypotensive activities of Timolol. Approved Tinoridine The therapeutic efficacy of Torasemide can be decreased when used in combination with Tinoridine. Investigational Tixocortol Tixocortol may increase the hypokalemic activities of Torasemide. Approved, Withdrawn Tizanidine The risk or severity of adverse effects can be increased when Torasemide is combined with Tizanidine. Approved, Investigational Tobramycin The serum concentration of Tobramycin can be increased when it is combined with Torasemide. Approved, Investigational Tolazamide The therapeutic efficacy of Tolazamide can be decreased when used in combination with Torasemide. Approved, Investigational Tolazoline Torasemide may increase the hypotensive activities of Tolazoline. Approved, Vet Approved Tolbutamide The metabolism of Torasemide can be decreased when combined with Tolbutamide. Approved, Investigational Tolcapone The risk or severity of adverse effects can be increased when Tolcapone is combined with Torasemide. Approved, Withdrawn Tolfenamic Acid The therapeutic efficacy of Torasemide can be decreased when used in combination with Tolfenamic Acid. Approved, Investigational Tolmetin The therapeutic efficacy of Torasemide can be decreased when used in combination with Tolmetin. Approved Tolonidine Torasemide may increase the hypotensive activities of Tolonidine. Experimental Toloxatone Toloxatone may increase the hypotensive activities of Torasemide. Approved Topiramate The risk or severity of hypokalemia can be increased when Torasemide is combined with Topiramate. Approved Topiroxostat The metabolism of Torasemide can be decreased when combined with Topiroxostat. Approved, Investigational Tramadol The risk or severity of adverse effects can be increased when Tramadol is combined with Torasemide. Approved, Investigational Trandolapril Torasemide may increase the hypotensive activities of Trandolapril. Approved Tranilast The therapeutic efficacy of Torasemide can be decreased when used in combination with Tranilast. Approved, Investigational Tranylcypromine Tranylcypromine may increase the hypotensive activities of Torasemide. Approved, Investigational Travoprost Torasemide may increase the hypotensive activities of Travoprost. Approved Treprostinil Torasemide may increase the hypotensive activities of Treprostinil. Approved, Investigational Tretinoin The risk or severity of adverse effects can be increased when Tretinoin is combined with Torasemide. Approved, Investigational, Nutraceutical Triamcinolone Triamcinolone may increase the hypokalemic activities of Torasemide. Approved, Vet Approved Triamterene The risk or severity of adverse effects can be increased when Torasemide is combined with Triamterene. Approved Tribenoside The therapeutic efficacy of Torasemide can be decreased when used in combination with Tribenoside. Experimental Trichlormethiazide Torasemide may increase the hypotensive activities of Trichlormethiazide. Approved, Vet Approved Trimazosin Trimazosin may increase the hypotensive activities of Torasemide. Experimental Trimethaphan Trimethaphan may increase the hypotensive activities of Torasemide. Approved, Investigational Trimethoprim The metabolism of Torasemide can be decreased when combined with Trimethoprim. Approved, Vet Approved Triptolide The therapeutic efficacy of Torasemide can be decreased when used in combination with Triptolide. Investigational Troglitazone The therapeutic efficacy of Troglitazone can be decreased when used in combination with Torasemide. Investigational, Withdrawn Trolamine salicylate The therapeutic efficacy of Torasemide can be decreased when used in combination with Trolamine salicylate. Approved Tubocurarine Torasemide may decrease the neuromuscular blocking activities of Tubocurarine. Approved Udenafil Udenafil may increase the antihypertensive activities of Torasemide. Approved, Investigational Ulobetasol Ulobetasol may increase the hypokalemic activities of Torasemide. Approved Unoprostone Torasemide may increase the hypotensive activities of Unoprostone. Approved, Investigational Urapidil Urapidil may increase the hypotensive activities of Torasemide. Investigational Valdecoxib The therapeutic efficacy of Torasemide can be decreased when used in combination with Valdecoxib. Approved, Investigational, Withdrawn Valproic Acid The metabolism of Torasemide can be decreased when combined with Valproic Acid. Approved, Investigational Valrubicin The serum concentration of Valrubicin can be increased when it is combined with Torasemide. Approved Valsartan The metabolism of Torasemide can be decreased when combined with Valsartan. Approved, Investigational Vardenafil Vardenafil may increase the antihypertensive activities of Torasemide. Approved Vecuronium Torasemide may decrease the neuromuscular blocking activities of Vecuronium. Approved Vemurafenib The serum concentration of Torasemide can be increased when it is combined with Vemurafenib. Approved Verapamil The risk or severity of adverse effects can be increased when Torasemide is combined with Verapamil. Approved Vilanterol Vilanterol may increase the hypokalemic activities of Torasemide. Approved Vildagliptin The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Torasemide. Approved, Investigational Vincamine Torasemide may increase the hypotensive activities of Vincamine. Experimental Vinpocetine Torasemide may increase the hypotensive activities of Vinpocetine. Investigational Voglibose The therapeutic efficacy of Voglibose can be decreased when used in combination with Torasemide. Approved, Investigational Voriconazole The metabolism of Torasemide can be decreased when combined with Voriconazole. Approved, Investigational Warfarin The metabolism of Warfarin can be decreased when combined with Torasemide. Approved Xipamide Torasemide may increase the hypotensive activities of Xipamide. Experimental Xylometazoline Torasemide may increase the hypotensive activities of Xylometazoline. Approved, Investigational Yohimbine Yohimbine may decrease the antihypertensive activities of Torasemide. Approved, Investigational, Vet Approved Zafirlukast The metabolism of Torasemide can be decreased when combined with Zafirlukast. Approved, Investigational Zaltoprofen The therapeutic efficacy of Torasemide can be decreased when used in combination with Zaltoprofen. Approved, Investigational Zileuton The therapeutic efficacy of Torasemide can be decreased when used in combination with Zileuton. Approved, Investigational, Withdrawn Zofenopril Torasemide may increase the hypotensive activities of Zofenopril. Experimental Zomepirac The therapeutic efficacy of Torasemide can be decreased when used in combination with Zomepirac. Withdrawn Zoptarelin doxorubicin The serum concentration of Zoptarelin doxorubicin can be increased when it is combined with Torasemide. Investigational Zorubicin The serum concentration of Zorubicin can be increased when it is combined with Torasemide. Experimental - Food Interactions
- Not Available
References
- Synthesis Reference
Fritz Topfmeier, Gustav Lettenbauer, "Process for the preparation of a stable modification of torasemide." U.S. Patent USRE0345806, issued June, 1975.
USRE0345806- General References
- Dunn CJ, Fitton A, Brogden RN: Torasemide. An update of its pharmacological properties and therapeutic efficacy. Drugs. 1995 Jan;49(1):121-42. [PubMed:7705212]
- Authors unspecified: FDA approved new drug bulletin: torsemide (Demadex), trimetrexate glucuronate (neuTrexin). RN. 1994 May;57(5):53-6. [PubMed:8197389]
- External Links
- Human Metabolome Database
- HMDB0014359
- KEGG Drug
- D00382
- PubChem Compound
- 41781
- PubChem Substance
- 46504760
- ChemSpider
- 38123
- BindingDB
- 64107
- ChEBI
- 9637
- ChEMBL
- CHEMBL1148
- Therapeutic Targets Database
- DAP000745
- PharmGKB
- PA451733
- RxList
- RxList Drug Page
- PDRhealth
- PDRhealth Drug Page
- Wikipedia
- Torasemide
- ATC Codes
- C03CA04 — Torasemide
- MSDS
- Download (110 KB)
Clinical Trials
- Clinical Trials
Pharmacoeconomics
- Manufacturers
- Hoffmann la roche inc
- Bedford laboratories
- Luitpold pharmaceuticals inc
- Meda pharmaceuticals inc
- Apotex inc etobicoke site
- Aurobindo pharma ltd
- Hetero drugs ltd
- Par pharmaceutical inc
- Pliva pharmaceutical industry inc
- Roxane laboratories inc
- Sun pharmaceutical industries ltd
- Teva pharmaceuticals usa inc
- Packagers
- American Regent
- Apotex Inc.
- Aurobindo Pharma Ltd.
- Camber Pharmaceuticals Inc.
- Cardinal Health
- Diversified Healthcare Services Inc.
- F Hoffmann-La Roche Ltd.
- General Injectables and Vaccines Inc.
- Greenstone LLC
- Heartland Repack Services LLC
- Hetero Drugs Ltd.
- Ivax Pharmaceuticals
- Mckesson Corp.
- Meda AB
- Murfreesboro Pharmaceutical Nursing Supply
- Neuman Distributors Inc.
- Palmetto Pharmaceuticals Inc.
- Par Pharmaceuticals
- Physicians Total Care Inc.
- Pliva Inc.
- Preferred Pharmaceuticals Inc.
- Prepak Systems Inc.
- Resource Optimization and Innovation LLC
- Roxane Labs
- Sun Pharmaceutical Industries Ltd.
- Teva Pharmaceutical Industries Ltd.
- UDL Laboratories
- Vangard Labs Inc.
- Dosage forms
Form Route Strength Tablet Oral 10 mg/1 Tablet Oral 100 mg/1 Tablet Oral 20 mg/1 Tablet Oral 5 mg/1 Liquid Intravenous 10 mg Tablet Oral 100 mg Tablet Oral 10 mg Tablet Oral 20 mg Tablet Oral 5 mg Injection Intravenous 10 mg/mL Injection, solution Intravenous 10 mg/mL - Prices
Unit description Cost Unit Demadex 100 mg tablet 5.69USD tablet Torsemide 100 mg tablet 3.16USD tablet Demadex 20 mg tablet 1.59USD tablet Demadex 10 mg tablet 1.39USD tablet Demadex 5 mg tablet 1.28USD tablet Torsemide 20 mg tablet 0.85USD tablet Torsemide 10 mg tablet 0.73USD tablet Torsemide 5 mg tablet 0.66USD tablet DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 164-164 °C Not Available water solubility Water soluble Not Available logP 2.3 Not Available pKa 7.1 Not Available - Predicted Properties
Property Value Source Water Solubility 0.0596 mg/mL ALOGPS logP 1.76 ALOGPS logP 1.86 ChemAxon logS -3.8 ALOGPS pKa (Strongest Acidic) 5.92 ChemAxon pKa (Strongest Basic) 4.2 ChemAxon Physiological Charge -1 ChemAxon Hydrogen Acceptor Count 5 ChemAxon Hydrogen Donor Count 3 ChemAxon Polar Surface Area 100.19 Å2 ChemAxon Rotatable Bond Count 4 ChemAxon Refractivity 91.89 m3·mol-1 ChemAxon Polarizability 36.15 Å3 ChemAxon Number of Rings 2 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET features
Property Value Probability Human Intestinal Absorption + 0.9156 Blood Brain Barrier + 0.6871 Caco-2 permeable - 0.5374 P-glycoprotein substrate Non-substrate 0.799 P-glycoprotein inhibitor I Non-inhibitor 0.7695 P-glycoprotein inhibitor II Non-inhibitor 0.8232 Renal organic cation transporter Non-inhibitor 0.9185 CYP450 2C9 substrate Substrate 0.6049 CYP450 2D6 substrate Non-substrate 0.9116 CYP450 3A4 substrate Non-substrate 0.7558 CYP450 1A2 substrate Non-inhibitor 0.9045 CYP450 2C9 inhibitor Non-inhibitor 0.6692 CYP450 2D6 inhibitor Non-inhibitor 0.923 CYP450 2C19 inhibitor Non-inhibitor 0.9025 CYP450 3A4 inhibitor Inhibitor 0.5905 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.6324 Ames test Non AMES toxic 0.9133 Carcinogenicity Non-carcinogens 0.8366 Biodegradation Not ready biodegradable 1.0 Rat acute toxicity 1.8740 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9854 hERG inhibition (predictor II) Non-inhibitor 0.8668
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as pyridinesulfonamides. These are heterocyclic compounds containing a pyridine ring substituted by one or more sulfonamide groups.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Pyridines and derivatives
- Sub Class
- Pyridinesulfonamides
- Direct Parent
- Pyridinesulfonamides
- Alternative Parents
- Toluenes / Sulfonylureas / Dihydropyridines / Secondary ketimines / Organosulfonic acids and derivatives / Heteroaromatic compounds / Aminosulfonyl compounds / Propargyl-type 1,3-dipolar organic compounds / Carboximidic acids and derivatives / Azacyclic compounds show 4 more
- Substituents
- Pyridine-3-sulfonamide / Dihydropyridine / Toluene / Sulfonylurea / Monocyclic benzene moiety / Hydropyridine / Benzenoid / Secondary ketimine / Heteroaromatic compound / Organic sulfonic acid or derivatives show 16 more
- Molecular Framework
- Aromatic heteromonocyclic compounds
- External Descriptors
- secondary amino compound, aminopyridine, N-sulfonylurea (CHEBI:9637)
Targets
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Sodium:potassium:chloride symporter activity
- Specific Function
- Electrically silent transporter system. Mediates sodium and chloride reabsorption. Plays a vital role in the regulation of ionic balance and cell volume.
- Gene Name
- SLC12A1
- Uniprot ID
- Q13621
- Uniprot Name
- Solute carrier family 12 member 1
- Molecular Weight
- 121449.13 Da
References
- Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
- Vormfelde SV, Sehrt D, Toliat MR, Schirmer M, Meineke I, Tzvetkov M, Nurnberg P, Brockmoller J: Genetic variation in the renal sodium transporters NKCC2, NCC, and ENaC in relation to the effects of loop diuretic drugs. Clin Pharmacol Ther. 2007 Sep;82(3):300-9. Epub 2007 Apr 25. [PubMed:17460608]
- Fortuno A, Muniz P, Ravassa S, Rodriguez JA, Fortuno MA, Zalba G, Diez J: Torasemide inhibits angiotensin II-induced vasoconstriction and intracellular calcium increase in the aorta of spontaneously hypertensive rats. Hypertension. 1999 Jul;34(1):138-43. [PubMed:10406837]
Enzymes
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Steroid hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
- Gene Name
- CYP2C8
- Uniprot ID
- P10632
- Uniprot Name
- Cytochrome P450 2C8
- Molecular Weight
- 55824.275 Da
References
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
- Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Steroid hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
- Gene Name
- CYP2C9
- Uniprot ID
- P11712
- Uniprot Name
- Cytochrome P450 2C9
- Molecular Weight
- 55627.365 Da
References
- Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
- Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Prostaglandin-endoperoxide synthase activity
- Specific Function
- Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gas...
- Gene Name
- PTGS1
- Uniprot ID
- P23219
- Uniprot Name
- Prostaglandin G/H synthase 1
- Molecular Weight
- 68685.82 Da
References
- Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Steroid hydroxylase activity
- Specific Function
- Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
- Gene Name
- CYP2C19
- Uniprot ID
- P33261
- Uniprot Name
- Cytochrome P450 2C19
- Molecular Weight
- 55930.545 Da
References
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Drug created on June 13, 2005 07:24 / Updated on March 02, 2018 01:54